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Chronic wasting disease (CWD) is a transmissible 
spongiform encephalopathy, or prion disease, that affects 
deer, elk, and moose. Human susceptibility to CWD remains 
unproven despite likely exposure to CWD-infected cervids. 
We used 2 nonhuman primate species, cynomolgus ma-
caques and squirrel monkeys, as human models for CWD 
susceptibility. CWD was inoculated into these 2 species by 
intracerebral and oral routes. After intracerebral inoculation 
of squirrel monkeys, 7 of 8 CWD isolates induced a clini-
cal wasting syndrome within 33–53 months. The monkeys’ 
brains showed spongiform encephalopathy and protease-
resistant prion protein (PrPres) diagnostic of prion disease. 
After oral exposure, 2 squirrel monkeys had PrPres in brain, 
spleen, and lymph nodes at 69 months postinfection. In con-
trast, cynomolgus macaques have not shown evidence of 
clinical disease as of 70 months postinfection. Thus, these 2 
species differed in susceptibility to CWD. Because humans 
are evolutionarily closer to macaques than to squirrel mon-
keys, they may also be resistant to CWD.
Transmissible spongiform encephalopathies (TSEs), or prion diseases, are neurodegenerative diseases that 
affect many mammalian species. Some examples include 
bovine spongiform encephalopathy (BSE) in cattle, scrapie 
in sheep and goats, Creutzfeldt-Jakob disease (CJD) in 
humans, and chronic wasting disease (CWD) in cervids. 
CWD was first found in captive deer in Colorado in 1967 
(1) and was later identified in several US states and Cana-
dian provinces (2). Epidemiologic evidence suggests that 
CWD continues to spread among cervid populations in 
North America (3), creating concern that CWD may cross 
species barriers to infect humans or domestic animals that 
may be eaten by humans. Thus, the host range of CWD and 
the level of protection provided by species barriers should 
be determined.
Substantial progress has been made in testing species 
barriers for CWD by using transgenic mice expressing 
species-specific prion protein (PrP), by direct infection into 
new species, or by in vitro conversion assays. The most 
sensitive method for testing susceptibility to TSE agents is 
intracerebral injection. Unfortunately, this route does not 
mimic most natural situations and only enables assessment 
of whether the possibility of transmission exists. Hamir et 
al. infected cattle and sheep with CWD by the intracerebral 
route and found protease-resistant PrP (PrPres) in 5 of 13 
cattle and 2 of 8 sheep, which indicated that these ruminant 
species can propagate CWD (4,5). However, oral exposure 
in these hosts apparently does not cause disease (2).
CWD cross-species transmission to nonagricultural 
and laboratory animals has shown variable levels of sus-
ceptibility depending on the route of transmission. For ex-
ample, ferrets were 100% susceptible to CWD by intrac-
erebral infection but were not susceptible to oral infection 
(6,7). Mink were only 25% susceptible to CWD by intrac-
erebral infection and were not susceptible to oral infection 
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Susceptibilities of Nonhuman Primates to CWD
(8). CWD has been successfully transmitted and adapted to 
laboratory rodents, including hamsters, transgenic mice ex-
pressing hamster PrP, and transgenic mice overexpressing 
mouse PrP (9,10). In contrast, transgenic mice expressing 
human PrP were not susceptible to CWD by intracerebral 
infection (11,12), a finding that provided evidence for a 
human species barrier against CWD infection. However, 
work started in 1980 and published in 2005 by Marsh et 
al. showed that 2 squirrel monkeys (Saimiri sciureus) in-
fected by the intracerebral route with brain homogenate 
from a single CWD-affected mule deer became clinically 
sick at 31 and 34 months postinfection, and both were posi-
tive for PrPres (13). This evidence that at least 1 species of 
nonhuman primate was susceptible to CWD weakened the 
conclusion that humans may be protected from CWD by a 
species barrier.
We addressed 4 questions raised by the original ob-
servation that squirrel monkeys are susceptible to CWD 
(13). First, we compared intracerebral and oral routes of 
infection. This comparison was of interest because the oral 
route is likely to be an important natural route of disease 
transmission, and susceptibility is known to be lower by 
this route in most models. Second, we compared 2 species 
of nonhuman primates, cynomolgus macaques (Macaca 
fascicularis) and squirrel monkeys, each of which has pre-
viously shown susceptibility to various human prion dis-
eases (14–16). However, humans are believed to be evo-
lutionarily closer to cynomolgus macaques than to squirrel 
monkeys (17), and cynomolgus macaques may be a more 
accurate model for a human species barrier. Third, because 
only 1 CWD source was tested by Marsh et al. (13), we 
studied 8 different pools of CWD representing wild and 
captive cervids, including mule deer, white-tailed deer, and 
elk, from separate regions in the United States. Fourth, we 
tested the species tropism of CWD agent passaged in squir-
rel monkeys.
Materials and Methods
A description of the materials and methods used in this 
study follows. Additional details are available in the online 
Technical Appendix, available from www.cdc.gov/EID/
content/15/9/1366-Techapp.pdf.
Animal Research
All monkeys and mice were housed at the Rocky 
Mountain Laboratories (Hamilton, MT, USA). Experimen-
tation followed protocols approved by the National Insti-
tutes of Health Rocky Mountain Laboratories Animal Care 
and Use Committee.
CWD Pools for Infection of Primates
CWD-positive brain homogenates were provided by 
E.S.W. and M.W.M. Contents of each pool were as fol-
lows: MD-1, 6 free-ranging mule deer from Wyoming 
(18); MD-2, 4 captive mule deer from Colorado; MD-3, 
28 captive mule deer from Wyoming and Colorado (2,19); 
WTD-1, 7 captive white-tailed deer from Wyoming and 
Colorado (18,20); WTD-2, 1 wild white-tailed deer from 
Wyoming; Elk-1, 2 free-ranging elk from Wyoming (18); 
Elk-2, 6 elk from a South Dakota game farm; and Elk-3, 10 
captive elk from Wyoming and Colorado. Normal elk brain 
was a pool from 2 elk from Montana obtained from Lynn 
Creekmore of the US Department of Agriculture.
Inoculation of Monkeys
For intracerebral injections, squirrel monkeys received 
either 2 mg or 20 mg brain in a total volume of 200 μL, and 
cynomolgus macaques received 5 mg in a total volume of 
500 μL. Oral doses of 200 mg brain/mL were given on 5 
different days at 2–6 day intervals. Squirrel monkeys re-
ceived 3-mL doses; most macaques received 4-mL doses. 
The inoculum was given to anesthetized animals through a 
rubber gastric tube.
Inoculation of Transgenic Mice
Brain homogenates diluted in phosphate buffered bal-
anced solution containing 2% fetal bovine serum were in-
oculated intracerebrally into young adult mice. Volumes 
were 50 μL.
Generation of Transgenic Mice Expressing Human PrP
Mice expressing human PrP (tgRM and tg66) were 
generated by using a transgene, cosSHa.HumPrP, which 
was created by ligating the human PrP open reading frame 
into the cosSHa.Tet vector (21). The transgene was inocu-
lated into eggs of FVBn–mouse PrP null mice in the labo-
ratories of R.R. (tg66) and L.C. (tgRM). Each line of mice 
overexpressed human PrP as tested by Western blot with 
monoclonal antibody 3F4.
Analysis of Protease-sensitive PrP  
and PrPres by Immunoblot
Tissues were prepared by making a 20% (wt/vol) ho-
mogenate in 0.01 M Tris buffer, pH 7.4. Samples to be 
analyzed for protease-sensitive PrP (PrPsen) contained 
the following protease inhibitors: 10 μmol/L leupeptin, 1 
μmol/L pepstatin A, and 1 μg/mL aprotinin. Samples were 
sonicated for 1 min and centrifuged at 5,000 rpm for 10 
min. Supernatants were mixed 1:1 in 2× sample buffer and 
boiled for 3 min before electrophoresis.
Preparation of samples for PrPres analysis has been 
described (18). Removal of carbohydrate residues from 
PrPres was performed by digestion with peptide-N-gly-
cosidase F (22).
After electrophoresis, proteins were transferred to Im-
mobilon polyvinylidene difluoride–P membranes (Milli-
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pore, Billerica, MA, USA), and PrP bands were detected 
with antibodies 3F4 (residues 109–112) (23), D13 (residues 
96–106) (24) (InPro Biotechnology, Inc., South San Fran-
cisco, CA, USA), or L42 (residues 145–163) (r-Biopharm, 
Darmstadt, Germany) (25). Bands were detected by using 
enhanced chemiluminescence substrate (GE Healthcare, 
Piscataway, NJ, USA).
Histopathologic and Immunohistochemical Analyses
Routine formalin fixation, embedding, and tissue-sec-
tioning protocols were followed. Tissues were stained with 
hematoxylin and eosin and analyzed for pathologic chang-
es. Immunohistochemical staining was performed by using 
an automated Nexus stainer (Ventana, Tucson, AZ, USA). 
Anti-PrP antibodies D13 and 3F4 were used for PrPres im-
munostaining as described (26,27).
Sequencing
Primate genomic DNA was purified from whole blood, 
and PCR products were amplified by using PuRe Taq Ready-
To-Go PCR beads (GE Healthcare). Two primers from the 
extreme outer ends of the open reading frame, including 
the previously published forward primer HM-1 (28) with 
mPrP-780R (5′-TCCCACTATCAGGAAGATGAGG-3′) 
or a combination of outer primers with internal primers 
mPrP-397F (5′-CCTTGGTGGCTACATGCTG-3′) and 
mPrP-416R (5′-CCAGCATGTAGCCACCAAG-3′), were 
used. Assembly comparisons were made against human, 
elk, mule deer, cynomolgus macaque, and squirrel monkey 
by using Sequencher version 4.6 (Gene Codes, Ann Arbor, 
MI, USA).
Results
Infectivity Levels in CWD Pools
When the 8 pools of CWD (representing both wild and 
captive deer and elk) used as inocula were analyzed by im-
munoblot, PrPres in the 8 pools showed similar electropho-
retic mobilities and glycoform patterns (Figure 1, panel A), 
but PrPres levels differed when quantitatively compared 
(Figure 1, panel C). To measure the level of infectivity in 
these pools, we titered each pool in transgenic mice ex-
pressing deer PrP (line 33; tgDeerPrP) (18). A typical end-
point dilution titration is shown in Figure 1, panel B. The 
8 pools had 50% infectious dose (ID50) titers ranging from 
6.3 × 107 to 5.0 × 108 ID50/g of brain homogenate (Figure 1, 
panel C). Comparison of titers with PrPres levels showed 
a partial correlation (Figure 1, panel C). For example, the 
CWD pool with the lowest infectivity titer (MD-2) was also 
the pool with the lowest PrPres level. However, for some 
pools, these tests showed discrepant values.
Intracerebral Infection of Squirrel Monkeys
 To test susceptibility to CWD, we inoculated squirrel 
monkeys with each of the 8 CWD pools described above. 
Of 13 squirrel monkeys, 11 became symptomatic (33–53 
mo postinfection [mpi]) (Table 1). The most consistent 
and reliable clinical finding was a severe wasting syn-
1368 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 9, September 2009
Figure 1. A) Western blot of chronic wasting disease (CWD) inocula showing protease-resistant prion protein (PrPres) in 8 CWD brain 
homogenate pools used for infecting nonhuman primates. Lane 1, 0.2-mg tissue equivalents of uninfected elk brain not treated with 
proteinase K; lanes 2–9, samples treated with proteinase K: lanes 2, 6, and 7, 0.12-mg tissue equivalents; lanes 3–5, 8, and 9, 0.67- 
mg tissue equivalents. PrPres was detected by using antibody L42 against PrP and enhanced chemiluminescence (GE Healthcare, 
Piscataway, NJ, USA). To provide optimal exposure for viewing PrP in all lanes, blot was exposed to film for 20 min. In this exposure, lanes 
2, 6, 7, and 8 were exposed beyond the linear range; this blot could not be used to quantify relative PrPres levels. Values on the left are in 
kDa. For more accurate quantitations of PrPres, other gels with different amounts loaded were exposed for multiple times (see panel C). B) 
Titration of MD-3 CWD inoculum. End-point infectivity titrations were calculated for each CWD inoculum by inoculating 50 µL of serial 10-
fold dilutions of each brain homogenate into transgenic mice expressing deer PrP, starting with a 1% (10–2) brain homogenate. Shown are 
data for an MD-3 inoculum. As the inoculum became more dilute, the incubation period (in days) and variability within a group increased. 
Each open circle represents 1 mouse in which clinical CWD developed. One mouse inoculated with a 10–6 dilution and 5 mice inoculated 
with a 10–7 dilution did not become sick after 625 days (solid circles). C) Infectivity titer and PrPres levels of each CWD pool. Titers are 
50% infectious dose/g of brain homogenate. Relative level (%) of PrPres in each pool was measured by Western blot with a combination 
of serial dilutions and sequential exposure times in the linear response range for each sample. Data obtained from these comparisons are 
summarized in the PrPres column. All pools were compared with the pool with the highest PrPres signal (Elk-2), which was set at 100%.
Susceptibilities of Nonhuman Primates to CWD
drome. Weight loss (average decrease of 33%) was most 
pronounced in the final few months of infection. Affected 
monkeys also had rough, poor-quality coats despite con-
tinuing to eat and drink. In the final 3–5 weeks, monkeys 
became weak and less active and spent most of their time 
hunched at the bottom of their cage. When the monkeys 
were encouraged to move, they did so slowly and delib-
erately. In the terminal stage of disease, a few had muscle 
tremors, excessive salivation, and mild ataxia. Fine, coor-
dinated movement such as eating food was rarely affected. 
Monkeys were euthanized when terminal-stage weakness 
and wasting compromised their mobility and ability to eat 
and drink.
No clear correlation between incubation period and 
amount of agent inoculated was noted (Table 1). For ex-
ample, 3 pairs of monkeys received the same inocula but in 
amounts that differed by 10-fold (Elk-1, Elk-3, and MD-1). 
Two pairs that received the lower dose became clinically 
sick first (Elk-1 and Elk-3). Both members of the third pair 
(MD-1) were euthanized after 36 months (Table 1). Two 
animals received the same dose of WTD-1 pool, yet to date, 
only 1 animal has become clinically sick. Animals that re-
ceived the CWD pool with the lowest titer (MD-2) had 
incubation periods similar to those receiving much higher 
titered inocula (Table 1).
In all monkeys with clinical signs, CWD was con-
firmed by Western blot detection of PrPres in brain (Fig-
ure 2, panels A, B). The glycoform pattern of PrPres was 
similar for all affected monkeys inoculated with different 
CWD pools (Figure 2, panel B). Because PrPres deposition 
may also occur outside the central nervous system, we also 
tested peripheral lymphoid tissues. For 3 of 11 monkeys 
that had PrPres in brain, PrPres was also found in spleen 
and lymph nodes (Figure 2, panel C). In general, PrPres 
levels were much lower in lymphoid tissues than in brain 
and were often not detected by Western blot. All nonlym-
phatic tissues tested (cardiac muscle, skeletal muscle, duo-
denum, jejunum, ileum, colon, salivary gland, kidney, and 
lung) were negative for PrPres by immunoblot.
Tissues from squirrel monkeys euthanized after intrac-
erebral injection with CWD (Table 1) were also examined 
by histopathologic analysis, including staining with hema-
toxylin and eosin and immunohistochemical detection of 
PrPres. All monkeys examined had spongiosis in the ce-
rebral cortex, caudate, putamen, and thalamus (Figure 3, 
panel A). In addition, PrPres deposition was observed in 
many brain regions with large PrPres-positive plaques in 
the thalamus, cerebellum, and spinal cord (Figure 3, panels 
C, E, F) and in smaller plaques spread out in the gray matter 
of the internal capsule and white matter of the corpus cal-
losum (Figure 3, panels G, H). The most abundant and con-
sistent location for PrPres staining was found in the frontal 
cortex and in the fiber tracts of the claustrum (Figure 3, 
panel I). The adjacent caudate had severe spongiosis and 
astrocytosis but minimal PrPres (Figure 3, panel I). PrPres 
was also detected in lymph nodes and spleen, within fol-
licles, in areas resembling follicular dendritic cells (Figure 
3, panels K, M). Immunohistochemical analysis showed no 
PrPres in heart, kidney, adrenal gland, skeletal muscle, sali-
vary gland, tongue, pancreas, white fat, and all regions of 
the gastrointestinal tract.
Oral Infection of Squirrel Monkeys
To test a more natural route of infection, we exposed 
squirrel monkeys orally to CWD. Of the 15 exposed squir-
rel monkeys, 1 (no. 345) was found dead in its cage at 
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Table 1. Results of squirrel monkey intracerebral inoculation with CWD agent* 
Monkey no.† PrP genotype‡ CWD inoculum Titer inoculated§ Incubation period, mpi¶ Weight change, % 
308 NT MD-1 1.0 × 106 36 –8
633 A MD-1 1.0 × 107 36 –42
334 B MD-2 6.4 × 105 43 –38
393 B MD-2 6.4 × 105 46 –28
640 A MD-3 2.0 × 106 44 –35
365 NT Elk-1 1.3 × 105 40 –43
643 A Elk-1 1.3 × 106 53 –27
321 NT Elk-2 4.0 × 105 35 –23
322 NT Elk-3 2.6 × 105 33 –40
624 A Elk-3 2.6 × 106 48 –37
399 A WTD-1 8.0 × 106 50 –33
628 NT WTD-1 8.0 × 106 NS (52) 0
310 A WTD-2 1.3 × 105 NS (69) +7
319 A Normal elk NS (69) –8
*CWD, chronic wasting disease; PrP, prion protein; mpi, months postinfection; NT, not tested (sequenced); NS, no signs. 
†In addition to the monkeys listed, 4 asymptomatic squirrel monkeys were euthanized at 10 mo after intracerebral inoculation with MD-1, MD-3, Elk-1, and 
WTD-1 to detect early accumulation of protease-resistant PrP (PrPres), but no PrPres was detected in brain by Western blot. 
‡See Table 4 for a description of genotypes A, B, and C. 
§Infectivity titers were determined by using endpoint dilution titer in transgenic deer expressing mouse PrP and are the 50% infectious dose/g of brain. 
¶Incubation periods for monkeys with clinical wasting are indicated as mpi in parentheses. NS indicates that these monkeys did not show any clinical signs 
compatible with transmissible spongiform encephalopathy or wasting. 
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69 mpi; it had shown no neurologic signs or weakness. 
Western blot results indicated PrPres in brain, spleen, and 
lymph nodes (Figure 2, panel D). The level of PrPres in 
the brain of monkey 345 was comparable with that in end-
stage intracerebrally inoculated monkeys; body weight 
at necropsy indicated a 33% decrease over the final 10 
months. The high levels of PrPres and the severe wasting 
indicate that CWD infection could have been the cause of 
death. A second monkey, 303, was euthanized at 69 mpi 
because of suspicion of TSE after 2 weeks of progressive 
weakness, wasting, and eventual anorexia. PrPres analysis 
confirmed PrPres in brain (Figure 2, panel D), spleen, and 
lymph nodes. For monkeys 303 and 345, levels of PrPres in 
the lymph nodes and spleens were 10–100-fold lower than 
those in brain.
Two other orally infected monkeys were euthanized 
during the first 69 mpi (Table 2). Monkey 301 was eutha-
nized at 39 mpi, after rapid onset of lethargy and anorexia 
that led to severe dehydration. Results of Western blot 
analysis for PrPres were negative in brain (Figure 1, panel 
B), spleen, lymph nodes, heart, skeletal muscle, duodenum, 
jejunum, ileum, colon, salivary gland, kidney, lung, and 
tonsil. However, immunohistochemical analysis detected 
PrPres in the spleen and 1 mesenteric lymph node from 
this monkey, indicating a low level of infection (Figure 3, 
panels J, K). Monkey 614 was euthanized at 44 mpi be-
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Figure 2. Western blots of squirrel monkey protease-resistant prion protein (PrPres). A) Brain homogenate from squirrel monkey 322, 
showing proteinase K (PK)–resistant PrPres. A downward shift of 7–9 kDa after PK digestion indicated a banding pattern typical of 
PrPres (lane 2). After deglycosylation with peptide-N-glycosidase F, 1 band of PrPres was present (lane 3). Lane 1, 0.5 mg of brain tissue 
equivalents; lane 2, 0.6 mg; lane 3, 0.4 mg. Blot was developed by using antibody 3F4 against PrP, enhanced chemiluminescence (ECL), 
and a 2-min exposure. B) Brains of monkeys screened for PrPres. All tissues were treated with PK, and lanes were loaded with 0.25 mg 
brain tissue equivalents, except for lane 5, which was loaded with 1.0 mg. All lanes contain samples of brain cortex except lanes 6 and 
7, which contain thalamus. Blot was developed by using antibody 3F4, ECL, and a 30-min exposure. Lane 1, control. In lanes 2–7, PrP 
banding is similar among squirrel monkeys infected with different pools of chronic wasting disease (CWD) agent (Table 1). PrPres was 
not detected in brain of orally infected squirrel monkey 301 (lane 8) or in brain of an intracerebrally infected cynomolgus macaque (Cm) 
609 (lane 9). C) Lymphatic tissues from squirrel monkey 365. For visualization of PrPres in lymph node and spleen, increased amounts 
of tissue were loaded, and a more sensitive detection system (femto detection; Thermo Scientific, Waltham, MA, USA) was used. Lane 
1, lymph node, 0.7 mg tissue equivalents; lane 2, spleen, 1.1 mg tissue equivalents. Blot was developed by using antibody 3F4, femto-
enhanced ECL, and a 1-min exposure. D) PK-treated brain and lymphatic tissues from orally infected squirrel monkeys 303 and 345. Lane 
1, positive control no. 640; lane 2, negative control; lane 3, no. 345 thalamus; lane 4, no. 303 thalamus; lane 5, no. 345 spleen; lane 6, no. 
345 mesenteric lymph node. Bands were visualized by using antibody 3F4 (residues 109–112) and ECL. Lanes 1–5, 10-min exposure; 
lane 6, overnight exposure; tissue equivalents loaded per lane: lanes 1–4, 0.25 mg; lane 5, 0.5 mg; lane 6, 1 mg. Values on the left of all 
blots are in kDa.
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cause it did not recover from anesthesia related to routine 
tuberculosis screening. Neither Western blot nor immuno-
histochemical analysis detected PrPres in brain, spleen, or 
lymph nodes of this monkey.
Infection of Cynomolgus Macaques
We inoculated cynomolgus macaques both orally and 
intracerebrally with 3 CWD inocula representing elk, mule 
deer, and white-tailed deer (Table 3). Of the cynomolgus 
macaques, 1 (no. 609) was euthanized at 48 mpi after it 
became aggressive. Brain (Figure 2, panel B), spinal cord, 
spleen, and lymph nodes were negative for PrPres by West-
ern blot and immunohistochemical analysis. All remaining 
CWD-inoculated cynomolgus monkeys are currently (at 70 
mpi) neurologically asymptomatic and have stable or in-
creased body weights.
Sequences
Amino acid substitutions in PrP can alter susceptibility 
to TSE agents, including CWD (18,29,30). To determine 
whether the lack of susceptibility in several intracerebrally 
inoculated squirrel monkeys (Table 1) was caused by PrP 
gene polymorphisms, we sequenced the PrP genes from 23 
squirrel monkeys. When compared with published squirrel 
monkey sequences (28,31), variation was seen at residue 
164, in the number of octapeptide repeats, and at residue 
19 of the signal peptide (Table 4). However, these genetic 
differences in PrP did not appear to account for the lack 
of susceptibility of monkey 310, which was genotype A, 
because this genotype was also found in 5 of the CWD-
positive monkeys. Because we were not able to sequence 
PrP of monkey 628, we could not assess the role of PrP 
variation in the lack of disease.
Infectivity of CWD-infected Squirrel Monkey Tissues  
in PrP Transgenic Mice
To determine whether passage of CWD in squirrel mon-
keys altered the tropism of the infectious agent, we inoculat-
ed tgDeerPrP mice and tg mice expressing human PrP (lines 
66 and RM) intracerebrally with tissue homogenates from 
3 CWD-positive squirrel monkeys (nos. 322, 308, and 301) 
with PrPres and from an intracerebrally inoculated cynomol-
gus macaque (no. 609). Clinical disease did not develop in 
any tgDeerPrP mice during 600–700 days (Table 5). The lack 
of transmission to tgDeerPrP, tg66, or tgRM mice from the 3 
squirrel monkeys with detectable CWD PrPres indicated that 
either the infectivity levels were low in these squirrel mon-
keys or that the original cervid species tropism was altered 
by the passage in squirrel monkeys. Similarly, the lack of 
transmission to tg mice expressing human PrP implied that 
passage through squirrel monkeys did not facilitate adapta-
tion to an agent with increased tropism for humans.
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Figure 3. Immunohistochemical analysis of squirrel 
monkeys infected with chronic wasting disease 
(CWD) agent. Panels A, C, and E–M are from squirrel 
monkeys infected with CWD. Panels B and D are from 
an uninfected monkey showing no pathologic changes 
or positive staining for protease-resistant prion protein 
(PrPres). Panels A and B, cerebral cortex stained with 
hematoxylin and eosin; panels C and D, thalamus 
stained with antibody 3F4 against PrP (arrows); panels 
E and F, cerebellar granular cell layer and spinal cord, 
respectively, stained with antibody 3F4; panel G, gray 
matter within the internal capsule stained with antibody 
D13 against PrP; panel H, corpus callosum (right) 
stained with antibody D13 showing more intense 
staining than the adjacent cortex (left); panel I, frontal 
cortex (fc), claustrum (cl), and caudate (ca) stained 
with antibody 3F4 (abundant vacuoles in the putamen 
[arrows]); panels J–M, lymphatic tissue stained with 
antibody 3F4; panels J and K, PrPres staining in 
spleen of monkey 322; panels L and M, PrPres-
positive mesenteric lymph node from orally infected 
monkey 301. Rectangles in panels J and L show areas 
enlarged in panels K and M, respectively. Antibodies 
D13 and 3F4 showed similar results for each monkey 
regarding the distribution, characteristics, and plaque 
size of PrPres. Scale bars: panels A–I, 50 µm; panel J, 
100 µm; panels K and M, 25 µm; panel L, 250 µm.
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Discussion
As new CWD foci continue to emerge among cervid 
populations, the risk for CWD transmission to humans 
needs to be assessed. We used 2 monkey species and 2 
routes of inoculation to test the susceptibility of primates to 
8 different pools of CWD. To date, we have verified CWD 
in 11 of 13 intracerebrally inoculated squirrel monkeys; 
average incubation period was 41 months (range 33–53 
months). Using a single CWD pool, Marsh et al. noted 
infection in 2 of 2 squirrel monkeys 31–34 months after 
intracerebral inoculation (13). Intracerebral inoculation of 
squirrel monkeys with other TSE agents, including agents 
of kuru, variant CJD, sporadic CJD, and sheep scrapie, 
had incubation periods of ≈24 months and attack rates of 
≈100% (14,15,32). The extended incubation periods and 
lower attack rates for our squirrel monkeys may result from 
a partial species barrier to CWD.
The signs of wasting syndrome in CWD-infected mon-
keys were similar to those of CWD infection in cervids, 
in which loss of body condition is nearly always a major 
component of infection and neurologic deficits vary (2). 
The correlation of clinical signs between CWD in cervids 
and squirrel monkeys suggests that CWD might affect a 
common brain region in each species. We observed PrPres 
deposition in squirrel monkeys primarily in the frontal lobe 
of the cerebral cortex, claustrum, putamen, and thalamus. 
Cervids typically have the most abundant and predictable 
PrPres in the dorsal motor vagus nucleus (obex), olfactory 
cortex, and diencephalon (including thalamus, hypothala-
mus, metathalamus, and epithalamus) (2,33). A plausible 
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Table 2. Results of squirrel monkey oral inoculation with CWD agent* 
Monkey no. PrP genotype† CWD inoculum Titer inoculated‡ Incubation period, mpi§ Weight change, % 
303¶ NT MD-1 1.5 × 109 69 –25
360 A MD-1 1.5 × 109 NS (69) +6
588 C MD-3 9.6 × 107 NS (52) +5
629 B MD-3 9.6 × 107 NS (52) 0
631 A Elk-1 1.9 × 108 NS (52) 0
335 NT Elk-2 6.0 × 108 NS (69) –5
656 B Elk-2 6.0 × 108 NS (52) –5
614# A Elk-2 6.0 × 108 44 –10
317 C Elk-3 3.9 × 108 NS (69) 0
301** NT Elk-3 3.9 × 108 39 –14
307 A WTD-1 1.2 × 109 NS (69) +8
345†† A WTD-1 1.2 × 109 69 –33
626 NT WTD-2 1.9 × 108 NS (52) +11
641 B WTD-2 1.9 × 108 NS (52) 0
325 NT WTD-2 1.9 × 108 NS (69) –8
655 A Buffer control NS (52) –6
314 NT Normal elk NS (69) +7
*CWD, chronic wasting disease; PrP, prion protein; mpi, months postinfection; NT, not tested (sequenced); NS, no signs. 
†See Table 4 for a description of genotypes A, B, and C. 
‡Infectivity titers were determined by using endpoint dilution titer in transgenic deer expressing mouse PrP and are listed as the 50% infectious dose/g of 
brain administered over 5 d at 2–6-d intervals. 
§Incubation periods for monkeys with clinical wasting are indicated as mpi in parentheses. NS indicates that these monkeys did not show any clinical 
signs compatible with transmissible spongiform encephalopathy (TSE) or wasting. 
¶Monkey 303 was euthanized at 69 mpi because of signs of wasting, weakness, and anorexia. 
#Monkey 614 was euthanized at 44 mpi because of complications arising from anesthesia for routine tuberculosis testing. No signs of TSE were observed 
before the complications, and Western blot and immunohistochemical results showed that this monkey was negative for protease-resistant PrP (PrPres). 
**Monkey 301 was euthanized at 39 mpi after a brief illness with signs of lethargy, anorexia, and dehydration. PrPres was detected in peripheral lymphoid 
tissues but not in brain. 
††Monkey 345 was found dead at 69 mpi. Brain, spleen, and lymph nodes were positive for PrPres by Western blot. 
Table 3. Cynomolgus macaques infected with CWD agent* 
No. monkeys CWD inoculum Route of inoculation Titer inoculated† Current mpi 
1 (no. 609)‡ MD-1 Intracerebral 2.5 × 106 NA
1 MD-1 Intracerebral 2.5 × 106 70
3 MD-1 Oral 2.0 × 109 70
2 Elk-1 Intracerebral 3.2 × 105 70
3 Elk-1 Oral 2.5 × 108 70
2 WTD-1 Intracerebral 1.0 × 106 70
3 WTD-1 Oral 1.2 × 109 70
*CWD, chronic wasting disease; mpi, months postinfection; NA, not available. 
†Infectivity titers were determined by using endpoint dilution titer in transgenic deer expressing mouse prion protein and are listed as the total 50% 
infectious dose/g of brain. 
‡Monkey 609 was euthanized at 48 mpi, and no protease-resistant prion protein was detected by Western blot or immunohistochemical analysis. 
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hypothesis could be that disruption of regions within the 
hypothalamus and thalamus leads to a metabolic imbal-
ance, resulting in a severe wasting syndrome.
We did not observe a strong correlation between in-
fectivity titer inoculated and attack incidence or incubation 
period (Table 1). One potential explanation is that the vari-
ation in speed of disease progression might not be relevant 
given the low number of animals in each group. A second 
possibility is that our squirrel monkeys varied at PrP alleles 
that may affect CWD susceptibility. However, analysis of 
23 squirrel monkeys showed no PrP sequence differences 
correlating with susceptibility to CWD (Tables 1, 2, 4). A 
third possibility is that genes other than the gene for PrP 
might influence CWD susceptibility.
For humans, eating infected or contaminated tissue 
is a likely route of CWD exposure. In other animal mod-
els, oral transmission of TSE is generally 1,000-fold less 
effective than direct intracerebral challenge and results 
in longer incubation periods and lower efficiency of dis-
ease transmission. In our oral transmission experiments, 
we found evidence of CWD infection in 3 monkeys; 2 
at 69 mpi had abundant PrPres in brain and lower levels 
in spleen and lymph nodes, and 1 euthanized at 39 mpi 
had PrPres in lymphatic tissues only. Thus, transmission 
seems to be slower by the oral route than by the intrac-
erebral route, and other orally infected monkeys may be 
affected in the future.
Cynomolgus macaques are evolutionarily closer to 
humans than are squirrel monkeys (17). At nearly 6 years 
postinoculation, no macaques have shown clinical signs of 
CWD. Intracerebral inoculation of cynomolgus macaques 
with BSE causes disease in 3 years; human variant CJD 
requires 2–3 years, and human sporadic CJD requires 5 
years (16,34). However, oral inoculation of cynomol-
gus macaques with BSE agent required a minimum of 5 
years before clinical disease was observed (35). There-
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Table 4. PrP sequence variability in squirrel monkeys* 
PrP gene variations‡
Genotype† No. monkeys Residue 19 No. octapeptide repeats Residue 164 
A 16 Leu/Leu 5/5 Lys/Lys 
B 5 ND 4/5 Lys/Lys 
C 2 Val/Leu 5/5 Lys/Lys 
Schätzl 1 Leu/Leu 5/5 Arg/Arg
Schneider 1 ND 4/4 Arg/Arg
*PrP, prion protein; ND, not determined. 
†The PrP genes of 23 monkeys were sequenced, and 3 genotypes were found. For easy reference to Tables 1 and 2, they are designated types A, B, 
and C. Previous squirrel monkey PrP sequences were identified by Schätzl et al. (28) and Schneider et al. (31). 
‡Compared with published sequences, PrP genotype variations were seen only at residue 19 (in the signal peptide), residue 164, and in the number of 
octapeptide repeats. 
Table 5. Infectivity of CWD agent from cervids, squirrel monkeys, and cynomolgus macaques in transgenic mice expressing deer PrP
or human PrP* 
TSE disease incidence§ 
Donor† Original inoculum Donor PrPres‡ tg33 (deer) tg66 (human) tgRM (human) 
SM 322¶ Elk-3 + 0/8 NT 0/6
SM 308¶ MD-1 + 0/7 0/8 0/8
SM 301 Elk-3 ± 0/6 NT NT
SM 320 Uninfected – 0/7 NT NT
CM 609 MD-1 – 0/8 NT NT
Elk-3 NA + 6/6 (301 ± 11) NT NT
MD-1 NA + 7/7 (323 ± 15) NT NT
sCJD (97–008) NA + NT NT 4/6 (170 ± 3) 
sCJD (99–009) NA + NT NT 5/5 (194 ± 20) 
sCJD (RR) NA + NT 8/8 (163 ± 1) NT
sCJD (PLG) NA + NT 4/4 (163 ± 6) NT
*CWD, chronic wasting disease; PrP, prion protein; TSE, transmissible spongiform encephalopathy; NT, not tested; sCJD, sporadic Creutzfeldt-Jakob 
disease. 
†Each donor monkey inoculum was prepared as a 1% brain homogenate from the indicated monkeys. SM, squirrel monkey; CM, cynomolgus macaque. 
Elk and mule deer CWD inocula were described in Materials and Methods. Human sCJD inocula are brain homogenates from World Health Organization 
CJD reference materials. No. 99–009 is sCJD M/M type I, and no. 97–008 is sCJD M/M type II. The RR sample was from a patient with sCJD of unknown 
PrP genotype. The PLG sample (M/M type I) was from a patient with sCJD. In all cases except sCJD (RR), 50 ?L was inoculated intracerebrally into 
recipient mice; for sCJD (RR), 30 ?L was inoculated. 
‡Based on Western blot or immunohistochemical analysis of brain for all except monkey 301, in which protease-resistant PrP (PrPres) was detected in 
spleen but not brain. 
§Number of recipient mice with clinical transmissible spongiform encephalopathy confirmed by detection of brain PrPres is the numerator, and total 
number of mice inoculated is the denominator. Mean ± SEM incubation period for time to clinical disease is provided in days. Tg33 mice express deer 
PrP, and tg66 and tgRM mice express human PrP. 
¶In addition to brain homogenate, we also inoculated tg33 mice with homogenates of spleen, lymph nodes, heart, muscle, and plasma from squirrel 
monkeys 322, 308, and 321, but disease did not develop during >600 d observation. 
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fore, we cannot rule out CWD transmission to cynomolgus 
macaques.
The PrP gene sequence can influence cross-species 
transmission of prion disease. Therefore, we compared 
squirrel monkey and cynomolgus macaque PrP gene se-
quences to look for differences that might account for 
different susceptibilities of these monkeys to CWD. In 
the PrP gene excluding the signal peptide, deer differed 
from squirrel monkeys at 17 residues and from cynomol-
gus macaques at 16 residues, but 14 of these differing 
residues were identical in squirrel monkeys and macaques 
(Figure 4). Therefore, there are only 2 residues in cyno-
molgus macaques (100 and 108) and 3 residues in squirrel 
monkeys (56, 159 and 182) at which these monkeys differ 
from deer and also from each other. These residues might 
play a role in susceptibility differences seen in our study.
Human exposure to CWD-infected cervids in past de-
cades is likely. The highest levels of prion infectivity are 
present in the central nervous system and lymphatic tissues 
of CWD-infected cervids; contamination of knives, saws, 
and muscles with these tissues can easy occur when pro-
cessing game. Despite the likelihood of exposures, epide-
miologic studies of humans living in CWD-endemic areas 
of Colorado and Wyoming during 1979–2001 have not 
shown any increases in human TSE cases (36,37). Ongo-
ing studies by the Colorado Department of Public Health 
and Environmental Human Prion Disease Surveillance 
Program, in conjunction with the University of Colorado 
School of Medicine, have also concluded that no convinc-
ing cases of CWD transmission to humans have been de-
tected in Colorado (38). However, if CWD in humans ap-
pears like a wasting syndrome similar to that observed in 
the squirrel monkeys in our study, affected persons might 
receive a diagnosis of a metabolic disorder and never be 
tested for TSE. Fortunately, additional laboratory data are 
consistent with the epidemiologic data, and these results 
support the conclusion that a species barrier protects hu-
mans from CWD infection (11–13,20,36,37).
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Figure 4. Comparison of prion protein 
sequences from various species. The 
following species are shown, and GenBank 
accession numbers are given when available: 
human (M13899), cynomolgus macaque 
(Cyno Mac) (U08298), squirrel monkey 
(Sq Mk) (genotype RML-A, see Table 4), 
squirrel monkey from Schneider et al. (31) 
(AY765385), squirrel monkey from Schätzl 
et al. (28) (U08310), mule deer (AY330343), 
and elk (AF156183). Numbering is based on 
the human sequence. Gray boxes indicate 
residues different from human residues. 
Alignment of the sequences was conducted 
with MegAlign software (DNAstar/Lasergene, 
Madison, WI, USA).
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